Mandate

Vinge advises Cellink in directed new issues of shares of MSEK 946

Vinge has advised Cellink in connection with directed new issues of shares of approximately 5.9 million class B shares which will generate MSEK 946 for Cellink.

The subscription price has been set through a so‑called accelerating book building procedure performed by Carnegie and J.P. Morgan and corresponds to a discount of 1.7% compared to the share’s closing date rate on Nasdaq Stockholm. Almost 4.3 million shares have been issued by virtue of the authorization resolved by the general meeting and approximately 1.6 million shares have been issued conditional upon approval by an extraordinary general meeting. The purpose of the new issues of shares is, in part, financing of the cash element of the purchase price for the acquisition of Scienion Ag., and, in part, to create scope for Cellink’s continued M&A agenda.

Vinge’s team primarily consisted of Anders StridEdin Agic and Victoria Gunnerek.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025